查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600977

注射市场：按分子类型、药物类别、注射途径和应用划分 - 2025-2030 年全球预测

Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug Class (Blood Factors, Cytokines, Immunoglobulin), Injection Routes, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年註射剂市值为5633亿美元，预计到2024年将达到6170.4亿美元，复合年增长率为9.86%，到2030年将达到10885.5亿美元。

市场区隔是製药业的动态部分，涵盖透过针头方法管理的各种产品，例如疫苗、生技药品、胰岛素和单株抗体。注射剂的需求是将药物快速输送到血液中，确保快速起效，这对于糖尿病、癌症和自体免疫疾病等急性疾病以及需要精确剂量的长期疾病非常重要。应用涵盖肿瘤学、内分泌学和神经学等治疗领域，最终用途包括医院、诊所、居家医疗机构，有时也用于透过笔式註射器或自动注射器自我给药。

主要市场统计
基准年[2023] 5633亿美元
预测年份 [2024] 6170.4亿美元
预测年份 [2030] 1,088,550 百万美元
复合年增长率（%） 9.86%

该市场主要由慢性病患病率上升、生技药品的进步以及疫苗需求的增加所推动。人口老化和不断扩大的医疗基础设施将进一步支持成长。新的商机在于生物相似药、无针输送系统和预填充式注射器，这些可以提高病患的依从性和安全性。此外，个人化医疗正在不断发展，与数位健康解决方案整合的智慧注射器的采用也在增加。然而，市场面临着诸如高成本、严格的监管要求以及注射剂的潜在副作用等挑战，这些副作用可能会影响合规性和可接受性。来自替代药物输送的竞争和对针头治疗的犹豫也构成了障碍。

为了发展您的业务，您可以将创新重点放在开发具有成本效益的生产技术、提高药物配方的稳定性以及改进输送系统以最大限度地减少注射相关的疼痛和焦虑。将物联网和人工智慧融入设备中可以即时监控和追踪依从性，从而改善患者的治疗效果。市场竞争仍然很激烈，需要持续的研发投资来应对这些挑战并利用成长机会。鼓励公司建立策略伙伴关係和联盟，以扩大其产品组合和市场占有率。驾驭这个复杂的市场需要采取灵活且富有远见的方法，深入研究尖端的药物传输技术和整体患者照护解决方案。

市场动态：揭示快速发展的注射剂市场的关键市场洞察

供需的动态交互作用正在改变注射药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病负担增加
    • 扩大预填充和自我治疗药物的使用
    • 药物传递在癌症治疗的持续普及
  • 市场限制因素
    • 增加产品召回
  • 市场机会
    • 注射剂的快速开发和核准
    • 注射剂製造商之间的策略联盟
  • 市场挑战
    • 製造流程复杂，注射剂供不应求

波特五力：驾驭注射药品市场的策略工具

波特的五力框架是了解注射市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解注射药品市场的外部影响

外部宏观环境因素在塑造注射剂市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解注射药品市场竞争状况

对注射剂市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：注射剂市场供应商的绩效评估

FPNV定位矩阵是评估注射剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病负担增加
      • 预填充药物和自行注射药物的使用增加
      • 受控药物传输载体在癌症治疗中的持续实践
    • 抑制因素
      • 产品回收数量增加
    • 机会
      • 注射剂的快速开发和核准
      • 注射剂製造商之间的策略联盟
    • 任务
      • 製造流程复杂，注射剂短缺
  • 市场区隔分析
    • 药物类别：细胞激素注射蛋白对细胞讯号传导的偏好增加
    • 应用：扩大注射剂在自体免疫疾病治疗的应用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化

第六章註射剂市场：依分子类型

  • 高分子
  • 小分子

第七章註射剂市场：依药物类别

  • 血液因素
  • 细胞激素
  • 免疫球蛋白
  • 胰岛素
  • 单株抗体
  • 肽激素

第八章註射剂市场：依注射途径

  • 肌肉注射
  • 眼
  • 椎管内的
  • 静脉
  • 皮下的

第九章註射剂市场：依应用分类

  • 自体免疫疾病
  • 心血管疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 疼痛

第10章美洲注射剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太注射剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲注射市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Sun Pharma 与 Taro 宣布合併协议
    • Glenmark 在印度推出了流行的抗糖尿病药物Liraglutide的生物相似药。
    • 百时美施贵宝的Opdivo注射液达到肾癌临床试验的关键目标

公司名单

  • Fresenius Kabi AG
  • SCHOTT PHARMA AG & CO. KGAA
  • F. Hoffmann-La Roche Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Sanofi SA
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Viatris Inc.
  • AstraZeneca PLC
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Ferring BV
  • Cipla Limited
  • Merck & Co., Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • AbbVie Inc.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Biogen Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • EVER Neuro Pharma GmbH
  • Chiesi Farmaceutici SpA
  • Eagle Pharmaceuticals, Inc.
  • Novo Nordisk A/S
Product Code: MRR-742BD517FCA4

The Injectable Drugs Market was valued at USD 563.30 billion in 2023, expected to reach USD 617.04 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 1,088.55 billion by 2030.

The injectable drugs market is a dynamic segment of the pharmaceuticals industry, encompassing a range of products administered by needle-based methods, including vaccines, biologics, insulin, and monoclonal antibodies, among others. The necessity of injectable drugs is underscored by their rapid delivery of medication into the bloodstream, ensuring quick onset of action, which is critical for acute conditions and long-term conditions requiring precise dosing such as diabetes, cancer, and autoimmune disorders. Applications extend to therapeutic areas like oncology, endocrinology, and neurology, with end-use spanning hospitals, clinics, home healthcare settings, and sometimes self-administration facilitated by pen injectors and auto-injectors.

KEY MARKET STATISTICS
Base Year [2023] USD 563.30 billion
Estimated Year [2024] USD 617.04 billion
Forecast Year [2030] USD 1,088.55 billion
CAGR (%) 9.86%

The market is primarily driven by the rising prevalence of chronic diseases, advancements in biologics, and increased demand for vaccines. Aging populations and expanding healthcare infrastructure further bolster growth. Emerging opportunities lie in biosimilars, needle-free delivery systems, and prefilled syringes that improve patient compliance and safety. Furthermore, personalized medicine is advancing, as is adoption of smart injectables with integrated digital health solutions. However, the market faces challenges such as high costs, stringent regulatory requirements, and potential side effects of injectable drugs that may affect compliance and acceptance. Competition from alternative drug delivery methods and hesitation over needle-based therapy also present hurdles.

For business growth, innovation could focus on developing cost-effective production technologies, improving drug formulation stability, and advancing delivery systems that minimize pain and anxiety associated with injections. Incorporating IoT and AI into devices can offer real-time monitoring and adherence tracking, thus enhancing patient outcomes. The market remains competitive and requires ongoing R&D investment to address these challenges and capitalize on growth opportunities. Companies are encouraged to form strategic partnerships and collaborations to expand their portfolios and market presence. Navigating this complex market will demand agility and a forward-thinking approach, delving into cutting-edge drug delivery technologies and holistic patient care solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Injectable Drugs Market

The Injectable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Burden of Chronic Diseases
    • Growing Use of Prefilled and Self-Injectable Drugs
    • Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
  • Market Restraints
    • Rise in Incidences of Product Recall
  • Market Opportunities
    • Rapid Developments and Approvals in Injectable Drugs
    • Strategic Alliances Among Manufacturers for Injectable Drugs
  • Market Challenges
    • Complex Manufacturing Process and Shortages of Injectable Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Injectable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Injectable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Injectable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Injectable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Injectable Drugs Market

A detailed market share analysis in the Injectable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Injectable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Injectable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Fresenius Kabi AG, SCHOTT PHARMA AG & CO. KGAA, F. Hoffmann-La Roche Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Sanofi S.A., Abbott Laboratories, Bristol-Myers Squibb Company, Viatris Inc., AstraZeneca PLC, Gilead Sciences, Inc., Daiichi Sankyo Co., Ltd., Ferring B.V., Cipla Limited, Merck & Co., Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Novartis AG, AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eli Lilly and Company, Pfizer Inc., EVER Neuro Pharma GmbH, Chiesi Farmaceutici S.p.A., Eagle Pharmaceuticals, Inc., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Large Molecule and Small Molecule.
  • Based on Drug Class, market is studied across Blood Factors, Cytokines, Immunoglobulin, Insulin, Monoclonal Antibodies, and Peptide Hormone.
  • Based on Injection Routes, market is studied across Intramuscular, Intraocular, Intrathecal, Intravenous, and Subcutaneous.
  • Based on Application, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Neurology, Oncology, and Pain.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Burden of Chronic Diseases
      • 5.1.1.2. Growing Use of Prefilled and Self-Injectable Drugs
      • 5.1.1.3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in Incidences of Product Recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid Developments and Approvals in Injectable Drugs
      • 5.1.3.2. Strategic Alliances Among Manufacturers for Injectable Drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex Manufacturing Process and Shortages of Injectable Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
    • 5.2.2. Application: Growing application of injectable drugs for treating autoimmune diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Injectable Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Large Molecule
  • 6.3. Small Molecule

7. Injectable Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Cytokines
  • 7.4. Immunoglobulin
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies
  • 7.7. Peptide Hormone

8. Injectable Drugs Market, by Injection Routes

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intraocular
  • 8.4. Intrathecal
  • 8.5. Intravenous
  • 8.6. Subcutaneous

9. Injectable Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiovascular Diseases
  • 9.4. Infectious Diseases
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Pain

10. Americas Injectable Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Injectable Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sun Pharma and Taro announce merger agreement
    • 13.3.2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
    • 13.3.3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

Companies Mentioned

  • 1. Fresenius Kabi AG
  • 2. SCHOTT PHARMA AG & CO. KGAA
  • 3. F. Hoffmann-La Roche Ltd.
  • 4. Dr. Reddy's Laboratories Ltd.
  • 5. Sun Pharmaceutical Industries Ltd.
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Sanofi S.A.
  • 9. Abbott Laboratories
  • 10. Bristol-Myers Squibb Company
  • 11. Viatris Inc.
  • 12. AstraZeneca PLC
  • 13. Gilead Sciences, Inc.
  • 14. Daiichi Sankyo Co., Ltd.
  • 15. Ferring B.V.
  • 16. Cipla Limited
  • 17. Merck & Co., Inc.
  • 18. Baxter International Inc.
  • 19. Boehringer Ingelheim International GmbH
  • 20. Novartis AG
  • 21. AbbVie Inc.
  • 22. Amgen Inc.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Biogen Inc.
  • 25. Eli Lilly and Company
  • 26. Pfizer Inc.
  • 27. EVER Neuro Pharma GmbH
  • 28. Chiesi Farmaceutici S.p.A.
  • 29. Eagle Pharmaceuticals, Inc.
  • 30. Novo Nordisk A/S

LIST OF FIGURES

  • FIGURE 1. INJECTABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INJECTABLE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023